Investing.com – Pfizer (NYSE:PFE) Q3 EPS estimated at $0.49; revenues seen up 7.2% yoy at $13.03 bn.
Global pharmaceutical firm reports Tuesday before the market opens.
Pfizer in September opted not to split business into two segments.
Prevenar 13 drug sales seen slowing; Lyrica to post single-digit growth until patent expires.
Dividend may be hiked from $0.30/quarter: attractive yield of 3.75%.
Even with P/E higher than sector average, Pfizer still seen safe investment.